(NYSE: MNK) today reported data from a Human Abuse Liability (HAL) study
in which both intact and crushed MNK-155 showed lower subjective
abuse-related effects than an immediate-release hydrocodone
bitartrate/acetaminophen formulation (a generic form of Vicodin ® ).
The data will be presented at PAINWeek 2014, a national conference on
pain for frontline practitioners, in Las Vegas, Nevada September 2-6,
for Mallinckrodt Pharmaceuticals Releases Human Abuse Liability (HAL) Data for Investigational MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination investment picks